Michelson Diagnostics’ VivoSight OCT scanner provides accurate diagnosis of early-stage BCC, reduces skin biopsies by 36%

NewsGuard 100/100 Score

Multi-centre, Prospective Study Data Published in Journal of Clinical and Aesthetic Dermatology

Michelson Diagnostics, a medical device company focused on applications of multi-beam Optical Coherence Tomography (‘OCT’) technology, today announces data showing that use of its VivoSight OCT scanner significantly improves diagnosis of basal-cell carcinoma (BCC) at an earlier stage and reduces diagnostic biopsies by 36%. Scanning with VivoSight OCT provides clinicians with continuous images of the epidermis and superficial dermis of the skin that can be interpreted by a medical professional during the diagnostic process. The data, from a multi-centre, prospective study conducted in the US is published in the October issue of the Journal of Clinical and Aesthetic Dermatology.

“The data showed that VivoSight OCT improved diagnostic certainty for BCC by a factor of four over clinical examination alone, and improved diagnostic accuracy by 50%,” explained Orit Markowitz, MD, Assistant Professor of Dermatology, the Icahn School of Medicine at Mount Sinai Hospital. “We also found that the addition of OCT to other standard assessments can improve the false-positive rate and give a high degree of certainty for ruling in a positive diagnosis for BCC. By sending these patients straight to surgery, we saw a 36% reduction in overall biopsies.”

Compared to clinical and dermascopic evaluation, VivoSight OCT significantly (p<0.01) improved sensitivity and specificity, correctly diagnosing in 87.8% of BCC cases compared to 57.4% for clinical and 69.6% for dermoscopy. The use of VivoSight OCT in the diagnosis of BCC also allowed more than 1 in 3 patients (36%) to avoid a diagnostic biopsy.

“This publication builds on existing excellent data showing that VivoSight scanning is emerging as a vital tool for the non-invasive diagnosis and monitoring of BCC and other non-melanoma skin cancers,” stated Andy Hill, Chief Executive Officer of Michelson Diagnostics. “Following the successful commercialisation of the VivoSight scanner in Europe and select markets internationally, Michelson Diagnostic is expanding potential applications of the OCT technology, including into melanoma diagnosis.”

VivoSight has CE/TGA regulatory-clearance and FDA 510(k) clearance in the United States. It is available for sale in Europe, USA and Australia.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Greenspace exposure boosts gut and skin microbiota health, study finds